---
document_datetime: 2023-09-21 18:58:22
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/insulin-human-winthrop-epar-procedural-steps-taken-authorisation_en.pdf
document_name: insulin-human-winthrop-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4353077
conversion_datetime: 2025-12-19 22:11:57.335986
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The  applicant  Sanofi-Aventis  Deutschland  GmbH  submitted  on  29  June  2006  an  application  for Marketing Authorisation to the European Medicines Agency (EMEA) for Insulin Human Winthrop through the centralised procedure.

The  legal  basis  for  this  application  refers  to  Article  10(c)  of  Directive  2001/83/EC,  as  amended  relating  to  informed  consent  from  a  marketing  authorisation  holder  for  the  authorised  medicinal product Insuman (EU/1/97/030/028/084).

## Licensing status:

The initial product, Insuman, has been given a Marketing Authorisation on 21 February 1997. The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Pieter Neels Co-Rapporteur: Frits Lekkerkerker 2. Steps taken for the assessment of the product · The application was received by the EMEA on 29 June 2006. · The procedure started on 21 July 2006. · The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  27 September  2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 03 October 2006 (revised 12 October 2006). · During  the  meeting  on  16-18  October  2006,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 19 October 2006. · The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  24 October 2006. · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 13 November 2006. · During  the  meeting  on  13-16  November  2006,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting  a  Marketing  Authorisation  to  Insulin  Human  Winthrop  on  16  November  2006.  The applicant  provided  the  letter  of  undertaking  on  the  follow-up  measures  to  be  fulfilled  postauthorisation on 10 November 2006. · The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 17 January 2007. Medicinal product no longer authorised